Ovarian Cancer PARPi Therapy
Current Landscape in Ovarian Cancer: PARP Inhibitors and Targeted Therapy

Released: December 03, 2020

Expiration: December 02, 2021

Activity

Progress
1
Course Completed

  1. Olaparib package insert. Wilmington, DE: AstraZeneca; 2020.
  2. Niraparib package insert. Research Triangle Park, NC: GlaxoSmithKline; 2020.
  3. Rucaparib package insert. Boulder, CO: Clovis Oncology; 2020.
  4. Clamp AR, James EC, McNeish IA, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet. 2019;394:2084.
  5. O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60:547-560.
  6. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-921.
  7. Sigorski D, Izycka-Swieszewska E, Bodnar L. Poly(ADP-ribose) polymerase inhibitors in prostate cancer: molecular mechanisms, and preclinical and clinical data. Target Oncol. 2020;Epub ahead of print.
  8. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, et al. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5:1137-1154.
  9. Tew WP, Lacchetti C, Ellis A, et al. PARP inhibitors in the management of ovarian cancer: ASCO Guideline. J Clin Oncol. 2020;38:3468.
  10. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154.
  11. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382.
  12. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274-1284.
  13. Fabbro M, Moore KN, Dorum A, et al. Efficacy and safety of niraparib as maintenance treatment in older patients (>/=70years) with recurrent ovarian cancer: results from the ENGOT-OV16/NOVA trial. Gynecol Oncol. 2019;152:560-567.
  14. Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949-1961.
  15. Ledermann J, Sehouli J, Zurawski B, et al. A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma. Program and abstracts of the ESMO 2017 Congress; September 8-12, 2017; Madrid, Spain. Abstract 2444.
  16. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852-861.
  17. Oaknin A, Ledermann JA, Oza AM, et al. Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3. Program and absracts of the 2018 ASCO annual meeting; June 1-5, 208; Chicago, Illinois.. Abstract 5545.
  18. Ledermann J, Oza A, Lorusso D, et al. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:710-722.
  19. Mirza MR, Gonzalez-Martin A, Graybill W, et al. Evaluation of an individualized starting-dose of niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study. Program and absracts of the 2020 ASCO annual meeting; May 29-31, 2020. Abstract 6050.
  20. Berek JS, Matulonis UA, Peen U, et al. Safety and dose modification for patients receiving niraparib. Ann Oncol. 2018;29:1784-1792.
  21. Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Program and abstracts of the ESMO 2020 Congress; September 19-21, 2020. Abstract 811MO.
  22. Gonzalez-Martin A, Pothuri B, Vorgote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391-2402.
  23. Pothuri B, Han S, Chase D, et al. Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial. Program and abstracts of the ESMO 2020 Congress; September 19-21, 2020. Abstract 810MO,
  24. Monk BJ and Gonzalez-Martin A. Paradigm Changes in Front Line Ovarian Cancer. Soc Gynecol Oncol Annual Meeting. 2020. https://sgoannualmeeting.org/wp-content/uploads/2020/04/Paradigm-Changes-in-Front-Line-Ovarian-Cancer.pdf.
  25. Gonzalez-Martin A, Pothuri B, Vergote I, et al. Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study). Program and abstracts of the ESMO 2019 Congress; September 27 - October 1, 2019; Barcelona, Spain. Abstract 4627.
  26. Han, SN, Monk BJ and Gonzalez-Martin A. Time to first subsequent therapy (TFST) and progression-free survival 2 (PFS2) from the phase 3 randomized, double-blind PRIMA/ENGOT-OV26/GOG-3012 study in patients with newly diagnosed ovarian cancer. Gynecol Oncol. 2020;159:18-19.
  27. Ray-Coquard I, Pautier P, Pignata et al. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (prs) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Program and abstracts of the ESMO 2019 Congress; September 27 - October 1, 2019; Barcelona, Spain. Abstract LBA2.
  28. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416-2428.
  29. Perren, TJ, Swart, AM, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011:365:2484-2496.
  30. Coleman R, Burger RA, Brady MF, et al. Analysis of survivorship in high-risk patients on treated on GOG-218. Gynecol Oncol. 2013;130:112-113
  31. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495-2505.
  32. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473-2483.
  33. Chan JK Brady MF, Penson RT, et al. Weekly vs every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016;374:738-748.
  34. Pilie PG, Tang C, Mills GB, et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16:81-104.